Story

The Full Story

For four years management told a story of records, super-cycles, and a company "becoming truly global." That story ended in FY2025 with operating profit cut in half, the FY2030 ¥300bn / 20% margin ambition quietly retired, the NKT Photonics acquisition reframed from "fourth pillar" to "make it profitable," and the CEO publicly conceding that the company had "been a bit lax in our thinking." The franchise — PMTs, opto-semis, scientific imaging — is intact and the moat has not failed; what has failed is the credibility of management's plan. The current narrative is more disciplined and less ambitious than the one investors bought in FY2024, and the FY2026 guide of only +6.4% OP confirms a multi-year rebuild rather than a snap-back.

1. The Narrative Arc

The arc has four distinct phases. A cautious pre-COVID baseline, a euphoric records era, a sudden destocking shock, and a contrite reset. Read left to right.

Phase 1 — Cautious baseline (FY2019, Hiruma). First mention of "global competition involving our products is becoming increasingly fierce" and explicit warning of "price competition in some parts of the market." This sentence reads, in hindsight, like the FY2025 narrative six years early.

Phase 2 — Records era (FY2021–FY2022, Hiruma → Maruno). "Highest ever sales and profits for two consecutive years." COVID-driven medical demand (PCR, X-ray CT for pneumonia, DNA sequencing) plus a semiconductor super-cycle drove revenue +44% and OP +124% across two years. Tadashi Maruno succeeds Akira Hiruma as President in December 2022, framed explicitly as continuity not change.

Phase 3 — First cracks (FY2023, Maruno). Record net sales again, but operating profit nudged down for the first time. Opto-semi OP fell 7.5% — "price competition from the emergence of competing manufacturers overseas" in dental flat panels. The China-as-pricing-threat narrative reappeared after a four-year absence, but in a single sentence.

Phase 4 — Destocking & reset (FY2024–FY2025). OP halved, then halved again. The company closed the long-running NKT Photonics acquisition (~€247m, twenty months of regulatory delay, final price >20% above original). FY2025 net sales recovered modestly but the operating profit collapse confirmed the prior cycle was not a transitory inventory correction. Maruno's Nov-2025 candor — "management foundation is weak" — is the rhetorical break.

2. What Management Emphasized — and Then Stopped Emphasizing

Each cell rates how prominently a theme was discussed in that year's annual / integrated report and presidential message. 0 = absent, 5 = central narrative pillar.

Three quiet pivots stand out.

EV / battery inspection — the hero theme that flipped. In FY2022 and FY2023 micro-focus X-ray sources for lithium-ion battery inspection were the headline growth narrative for the Electron Tube segment. By FY2025 the same product line is cited as a drag — "stagnant EV market." Management never explicitly walked back the original thesis; the topic simply went silent and re-emerged on the other side of the ledger.

The "record" drumbeat — silenced. "Record sales and profits" appeared in three consecutive presidential messages (FY2021, FY2022, FY2023). It is absent from FY2024 and FY2025. Replaced by the language of "reactionary period" and "recovery period."

FP&A / cost discipline — newly important. Until FY2024 the narrative had no concept of capital efficiency. By FY2025 Maruno is explicitly invoking ROE below cost of equity, FP&A thinking, headcount restraint, ERP unification, and a 240-day cash conversion cycle target. This is the language of a company that has just been told by the market that its prior framing was too forgiving.

3. Risk Evolution

Hamamatsu does not file a US-style risk factors section in its Integrated Report (the formal risks live in the Yuho, which is not in this corpus). What can be tracked is the operating risk inventory management actually surfaced in business and MDA narrative across years. The shift from sustainability-shaped boilerplate to specific, named operational risks is the real signal.

Four risks newly visible since FY2023:

• Chinese price competition moved from a single dental-sensor sentence (FY2023) to a named drag across both medical opto-semi and failure-analysis systems (FY2025).
• Customer inventory / destocking is the FY2024 explanation that became a year-long reality through FY2025. Management's framing shifted from "reactionary decline" (FY2024 — implies fast resolution) to "prolonged elimination of excess customer inventory" (FY2025).
• NIH / academic budget cuts appear for the first time in FY2025 as an explicit drag on PMT for medical analysis.
• NKT integration risk crystallized: ~¥10bn of M&A-related SG&A in FY2025, segment loss widened to ¥4.4bn vs ¥0.2bn the year before, and the "profitable in three years from FY2024" promise has slipped to FY2028.

The Integrated Report's sustainability disclosures (TCFD, named flood scenario at the Tenryu River–adjacent Shingai Factory, supplier code of conduct, human-rights due diligence, whistleblower counts) became substantively more candid FY2023→FY2024. That arc is positive. The operating risk arc is not.

4. How They Handled Bad News

The FY2025 guidance trajectory is the most informative single sequence in the company's recent history.

The pattern: Q1 OP fell 62.7% but guidance was held verbatim. Q2 1H OP missed by 11% and guidance was held with a hedge ("we may revise"). Q3 forced a 25% OP cut. The full-year actual then missed even the cut by ¥1.8bn. Sales finished close to plan; the entire shortfall was margin.

What changed in how management discussed the misses:

• FY2024 (Nov 2024 messaging): profit halving framed as a deliberate "Future upfront investment period" — discretionary, not deteriorating.
• Q1 FY25: -62.7% OP framed as already-improving Q4 momentum disrupted by short-term inventory; guidance held.
• Q3 FY25: capitulation — formal cut, blamed primarily on US tariff uncertainty plus continued China and opto-semi softness.
• Q4 FY25 (Nov 2025): for the first time in the corpus, no external factor frames the miss. Maruno: "We have been growing steadily for many years and have been a bit lax in our thinking." And: "the management foundation is weak."

5. Guidance Track Record

The pattern is uncomfortable. On revenue, management hits within ~3–10% — call that broadly fine. On operating profit, management has missed initial guidance by 33–34% in two of the last three years. The two big OP misses had different stated causes (FY2024 destocking; FY2025 China + NKT + medical) which itself is a problem: it suggests the planning process is not internalizing recurring downside scenarios.

The mid-term plan track record is worse. The ¥259.1bn / ¥37.7bn FY2027 target announced in FY2024 has been replaced one fiscal cycle later by ¥262bn / ¥33.6bn for FY2028 — i.e., a one-year deferral on top line and a ¥4bn cut to OP. The FY2030 ¥300bn / >20% margin ambition simply does not appear in the FY2025 plan. It has been retired without acknowledgment.

Credibility score: 5 / 10. Two consecutive ~33% OP misses against initial guidance, a quietly retired long-term target, and three quarters of holding a guide that internal data was disproving all argue for a low number. The score is not lower because (a) revenue has tracked plan within a tight band — execution on demand is honest; (b) Maruno's Q4 FY25 admission was unusually direct for a Japanese listed company; (c) the structural responses (NKT profitability project, FP&A, headcount discipline, ERP unification, ROE-anchored capital plan) match the diagnosis rather than deflect from it. The next two prints will move this number meaningfully in either direction.

6. What the Story Is Now

The current story, as management tells it after FY2025: a 70-year photonics franchise with a near-monopolistic PMT position and a leading silicon-photodiode/sCMOS portfolio is rebuilding from a margin reset triggered by Chinese price competition in dental opto-semis, the EV inspection slowdown, NIH-driven softness in academic PMT demand, and the M&A drag of an over-priced NKT acquisition. Recovery is guided modestly — FY2026 OP +6.4% to ¥17.2bn — and the new mid-term path to FY2028 (¥262bn / 12.8% margin / ROE >8%) is materially less ambitious than the plan it replaced.

What has been de-risked:

• The franchise. Industrial sales grew 12% in FY2025; semicon failure analysis is recovering on AI capex; Stealth Dicing is firm; Hyper-Kamiokande PMT contract is ongoing; quantum-computing laser supply (IonQ, Quantinuum, QuEra) is real revenue.
• Capital allocation transparency. Three-year ¥317bn capital plan (capex ¥84bn, R&D ¥58bn, returns ¥55bn, M&A ¥30bn). DOE 3.5% floor on dividends. ¥40bn of buybacks announced and largely executed. Treasury share cancellation of 11M shares completed April 2025.
• The destocking cycle itself. Q1 FY2026 opto-semi sales rose 8.8% YoY — volumes are back even as margins lag.

What still looks stretched:

• NKT Photonics. Loss widened in Q1 FY2026; the FY2028 profitability commitment is now on the third commitment timeline.
• The FY2028 mid-term plan. Requires +20bn of OP from a ¥16bn base in three years — a steeper trajectory than the FY2024 plan delivered against an easier starting point.
• China. Sales flat, price competition explicit, still ~19% of revenue and growing in opto-semi/dental — not yet sized as a structural drag in management's framing.
• Margins. Operating margin 7.6% is the lowest in the available eight-year history; restoring even FY2023's 25.6% requires more than mix recovery.

What the reader should believe versus discount.

Believe	Discount
The franchise — PMT, opto-semi, scientific imaging — is intact	"Stable growth from FY26" — already softened to +6.4% OP
Capital return commitment (DOE floor, ongoing buybacks)	The FY2030 ¥300bn / 20% margin ambition
China price competition is structural, not cyclical	"NKT profitable in three years" — third version of this promise
Maruno's candor and the FP&A/ERP/headcount discipline are real	The implicit claim that initial FY26 guidance is conservative — Q1 FY26 OP -43.9%
Semiconductor / AI is a genuine new growth pillar	That medical-bio's ¥10bn miss vs FY25 plan was one-time

The Hamamatsu franchise is not the issue. The plan that managed it for the last three years was. The plan now in front of investors is more disciplined and more modest, which is the right response — and the lower target is itself the cost of credibility being rebuilt.